53P HER2 low by immunohistochemistry (IHC) and gene expression by qRT-PCR using OncotypeDX in ER+ early breast cancer
M. Gaudio(Humanitas University), A. Zambelli(Humanitas University), Rita De Sanctis(Humanitas University), Giuseppe Saltalamacchia, Armando Santoro(IRCCS Humanitas Research Hospital), F. Jacobs(Humanitas University), C. Benvenuti
Cited by 1
Related Papers
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
|JAMA|2014|569
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532